WHAT IS CLAIMED IS:

1. A compound of the formula:



wherein R represents C_1-C_{20} alkyl, C_2-C_6 alkenyl, C_1-C_6 alkylaryl, C_1-C_6 alkyl(C_3-C_{10})cycloalkyl, C_1-C_6 alkyl-N,N-C_1-C_6 dialkylamine, C_1-C_6 alkyl-pyrrolidine, C_1-C_6 alkyl-piperidine, C_1-C_6 alkyl-morpholine or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1 wherein R represents C_1-C_{10} alkyl.

3. A compound according to claim 2 wherein R represents 2-ethyl butyl, isobutyl, 3-methyl butyl, decyl, or ethyl.

4. A compound according to claim 3 wherein R represents 2-ethyl butyl,

5. A compound according to claim 3 wherein R represents isobutyl.

6. A compound according to claim 3 wherein R represents 3-methyl butyl.

7. A compound according to claim 3 wherein R represents decyl.

8. A compound according to claim 3 wherein R represents ethyl.

9. A compound which is (3*S*,4a*R*,6*R*,8a*R*)-6-[2-(1H-Tetrazol-5-yl)-ethyl] - 1,2,3,4,4a,5,6,7,8,8a-decahydro-isoquinoline-3-carboxylic acid 2-ethyl-butyl ester, or a pharmaceutically acceptable salt thereof.

10. A compound according to claim 9 wherein the pharmaceutically acceptable salt is a trifluoroacetate salt.

11. A compound which is (3*S*,4a*R*,6*R*,8a*R*)-6-[2-(1H-Tetrazol-5-yl)-ethyl] - 1,2,3,4,4a,5,6,7,8,8a-decahydro-isoquinoline-3-carboxylic acid isobutyl ester, or a pharmaceutically acceptable salt thereof.

12. A compound according to claim 11 wherein the pharmaceutically acceptable salt is a trifluoroacetate salt.

13. A compound which is (3*S*,4a*R*,6*R*,8a*R*)-6-[2-(1H-Tetrazol-5-yl)-ethyl] - 1,2,3,4,4a,5,6,7,8,8a-decahydro-isoquinoline-3-carboxylic acid 3-methyl butyl ester, or a pharmaceutically acceptable salt thereof.

14. A compound according to claim 13 wherein the pharmaceutically acceptable salt is a trifluoroacetate salt.

15. A compound which is (3*S*,4a*R*,6*R*,8a*R*)-6-[2-(1H-Tetrazol-5-yl)-ethyl] - 1,2,3,4,4a,5,6,7,8,8a-decahydro-isoquinoline-3-carboxylic acid decyl ester, or a pharmaceutically acceptable salt thereof.

16. A compound according to claim 15 wherein the pharmaceutically acceptable salt is a trifluoroacetate salt.

17. A compound which is (3*S*,4a*R*,6*R*,8a*R*)-6-[2-(1H-Tetrazol-5-yl)-ethyl] - 1,2,3,4,4a,5,6,7,8,8a-decahydro-isoquinoline-3-carboxylic acid ethyl ester, or a pharmaceutically acceptable salt thereof.

18. A compound according to claim 15 wherein the pharmaceutically acceptable salt is a hydrochloride salt.

19. A compound which is (3*S*,4a*R*,6*R*,8a*R*)-6-[2-(1H-Tetrazol-5-yl)-ethyl] - 1,2,3,4,4a,5,6,7,8,8a-decahydro-isoquinoline-3-carboxylic acid ethyl ester hydrochloride monohydrate.

20. A pharmaceutical composition, which comprises a compound as claimed in Claim 1 and a pharmaceutically acceptable diluent or carrier.

21. A pharmaceutical composition for the treatment of pain or migraine, which comprises a compound as claimed in Claim 1 and a pharmaceutically acceptable diluent or carrier.

22. A method of treating pain, which comprises administering to a patient an effective amount of a compound of the formula:



wherein R represents C_1-C_{20} alkyl, C_2-C_6 alkenyl, C_1-C_6 alkylaryl, C_1-C_6 alkyl(C_3-C_{10})cycloalkyl, C_1-C_6 alkyl-N,N-C_1-C_6 dialkylamine, C_1-C_6 alkyl-pyrrolidine, C_1-C_6 alkyl-piperidine, C_1-C_6 alkyl-morpholine or a pharmaceutically acceptable salt thereof.

23. A method of treating migraine, which comprises administering to a patient an effective amount of a compound of the formula:



wherein R represents C_1-C_{20} alkyl, C_2-C_6 alkenyl, C_1-C_6 alkylaryl, C_1-C_6 alkyl(C_3-C_{10})cycloalkyl, C_1-C_6 alkyl-N,N-C_1-C_6 dialkylamine, C_1-C_6 alkyl-pyrrolidine, C_1-C_6 alkyl-piperidine, C_1-C_6 alkyl-morpholine or a pharmaceutically acceptable salt thereof.

24. The use of a compound as claimed in Claim 1 for the manufacture of a medicament for the treatment of pain.

25. The use of a compound as claimed in Claim 1 for the manufacture of a medicament for the treatment of migraine.

5